LCN2 and COVID-19: Furthermore, as clinical situations such as COVID-19, which is a pro-inflammatory and systemic infection, AKI manifests as a complication that worsens the patient’s clinical condition, which can lead to loss of function and death, and the use of biomarkers, especially urinary NGAL, have proven useful for predicting the prognosis of the infected patients36.